The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2017

Filed:

Jun. 27, 2016
Applicant:

Immunomedics, Inc., Morris Plains, NJ (US);

Inventors:

Hans J. Hansen, Picayune, MS (US);

Zhengxing Qu, Warren, NJ (US);

David M. Goldenberg, Mendham, NJ (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/40 (2006.01); C07K 16/28 (2006.01); A61K 47/48 (2006.01); A61K 51/10 (2006.01); A61K 45/06 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C07K 1/00 (2006.01); C07K 16/00 (2006.01); C12P 21/08 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/4863 (2013.01); A61K 47/48561 (2013.01); A61K 51/1027 (2013.01); A61K 51/1069 (2013.01); A61K 51/1093 (2013.01); C07K 16/283 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C07K 16/468 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser9lPhe substitution in the hA19 VH sequence.


Find Patent Forward Citations

Loading…